Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 208-215

  Corradini, Paolo ^a   Voena, Claudia ^a   Tarella, Corrado ^a   Astolfi, Monica ^a   Ladetto, Marco ^a   Palumbo, Antonio ^a   Van Lint, Maria Teresa ^a   Bacigalupo, Andrea ^a   Santoro, Alessandra ^a   Musso, Maurizio ^a   Majolino, Ignazio ^a   Boccadoro, Mario ^a   Pileri, Alessandro ^a  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; VINCRISTINE;

ADULT; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CELL TRANSPLANTATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REMISSION; WHOLE BODY RADIATION;

EID: 0032895599     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.208     Document Type: Article

References (33)

1. Boccadoro M, Pileri A: Diagnosis, prognosis, and standard treatment for multiple myeloma. Hematol Oncol Clin North Am 11:111-131, 1997
2. Attal M, Huguet F, Schlaifer D, et al: Intensive combined therapy for previously untreated aggressive myeloma. Blood 79:1130-1138, 1992
3. Harousseau JL, Milpied N, Laporte JP, et al: Double-intensive therapy in high-risk multiple myeloma. Blood 79:2827-2833, 1992
4. Anderson KC, Andersen J, Soiffer R, et al: Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 82:2568-2576, 1993
5. Gianni M, Tarella C, Bregni M, et al: High-dose sequential (HDS) chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 12:503-509, 1994
6. Barlogie B, Jagannath S, Vesole DH, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789-793, 1997
7. Attal M, Harousseau JL, Stoppa AM, et al: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
8. Bensinger WI, Buckner CD, Anasetti C, et al: Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 88:2787-2793, 1996
9. Gahrton G, Tura S, Ljungman P, et al: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13:1312-1322, 1995
10. Bjorkstrand B, Ljungman P, Svensson H, et al: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711-4718, 1996
11. Tricot G, Vesole DH, Jagannath S, et al: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196-1199, 1996
12. Verdonck LF, Lokhorst HM, Dekker AW, et al: Graft-versus-myeloma effect in two cases. Lancet 347:800-801, 1996
13. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90:4206-4211, 1997
14. Corradini P, Voena C, Astolfi M, et al: High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85:1596-1602, 1995
15. Schiller GJ, Vescio RA, Freytes C, et al: Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390-397, 1995
16. Lemoli R, Fortuna A, Motta MR, et al: Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 87:1625-1634, 1996
17. Bjorkstrand B, Ljungman P, Bird JM, et al: Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 15:367-371, 1995
18. Bird JM, Russell NH, Samson D: Minimal residual disease after bone marrow transplantation for multiple myeloma: Evidence for cure in long-term survivors. Bone Marrow Transplant 12:651-655, 1993
19. Voena C, Ladetto M, Astolfi M, et al: A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11:1793-1798, 1997
20. Corradini P, Boccadoro M, Voena C, et al: Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cμ sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 178:1091-1096, 1993
21. Billadeau D, Quam L, Thomas W, et al: Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 80:1818-1824, 1992
22. Vescio RA, Han EJ, Schiller GJ, et al: Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 18:103-110, 1996
23. Omedè P, Tarella C, Palumbo A, et al: Multiple myeloma: Reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. Br J Haematol 99:685-691, 1997
24. Gribben JG, Neuberg D, Freedman AS, et al: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3457, 1993
25. Provan D, Zwicky C, Bartlett-Pandite L, et al: Eradication of PCR detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88:2228-2235, 1996
26. Kantarjian HM, O'Brien S, Anderlini P, et al: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87:3069-3081, 1996
27. Lo Coco F, Diverio D, Pandolfi PP, et al: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 340:1437-1443, 1992
28. Corradini P, Astolfi M, Cherasco C, et al: Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 89:724-731, 1997
29. Elmaagacli AH, Beelen DW, Becks HW, et al: Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation. Bone Marrow Transplant 18:397-403, 1996
30. Bacigalupo A, van Lint MT, Valbonesi M, et al: Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Blood 88:353-357, 1996
31. Mielcarek M, Graf L, Gretchen J, et al: Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 92:215-222, 1998
32. Majolino I, Saglio G, Scimè R, et al: High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic disease. Bone Marrow Transplant 17:555-560, 1996
33. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997